Tumor oncogene (KRAS) status and risk of venous thrombosis in patients with metastatic colorectal cancer

Publisher： John Wiley & Sons Inc

E-ISSN： 1538-7836|13|6|998-1003

ISSN： 1538-7933

Source： JOURNAL OF THROMBOSIS AND HAEMOSTASIS, Vol.13, Iss.6, 2015-06, pp. : 998-1003

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Venous Thromboembolism and Port-Related Thrombosis in Metastatic Colorectal Cancer Patients: A Monocenter Experience

By  

Pathophysiology of Haemostasis and Thrombosis, Vol. 37, Iss. 1, 2010-10 ,pp. : 30-34

Karger

Access to resources Recommend Favorite

Clinical and Economic Aspects of KRAS Mutational Status as Predictor for Epidermal Growth Factor Receptor Inhibitor Therapy in Metastatic Colorectal Cancer Patients

By  

Oncology, Vol. 81, Iss. 5-6, 2012-01 ,pp. : 359-364

Karger

Access to resources Recommend Favorite

Cetuximab plus FOLFOX for Patients with Metastatic Colorectal Cancer with Poor Performance Status and/or Severe Tumor-Related Complications

By  

Case Reports in Oncology, Vol. 3, Iss. 2, 2010-07 ,pp. : 282-286

Karger

Access to resources Recommend Favorite

Phase II Trial of Cetuximab plus Irinotecan for Oxaliplatin- and Irinotecan-Based Chemotherapy-Refractory Patients with Advanced and/or Metastatic Colorectal Cancer: Evaluation of Efficacy and Safety Based on KRAS Mutation Status (T-CORE0801)

By  

Oncology, Vol. 87, Iss. 1, 2014-06 ,pp. : 7-20

Karger

Access to resources Recommend Favorite

The Role of KRAS Mutations in Predicting the Efficacy of Cetuximab-Plus-Irinotecan Therapy in Irinotecan-Refractory Korean Metastatic Colorectal Cancer Patients

By  

Oncology, Vol. 77, Iss. 3-4, 2009-09 ,pp. : 224-230

Karger

Access to resources Recommend Favorite